Buzdar A U, Gutterman J U, Blumenschein G R, Hortobagyi G N, Tashima C K, Smith T L, Hersh E M, Freireich E J, Gehan E A
Cancer. 1978 Mar;41(3):1064-75. doi: 10.1002/1097-0142(197803)41:3<1064::aid-cncr2820410340>3.0.co;2-q.
For the past 34 months, a combination of 5-fluorouracil, adriamycin, cyclophosphamide, and BCG (FAC-BCG) was evaluated as adjuvant treatment in stage II and III breast cancer patients with positive axillary nodes. In the group of 131 patients receiving FAC-BCG, the estimated proportion remaining disease-free at 2 years from surgery was 91% compared to an estimated 69% in a group of 151 historical control patients (p less than .01). This advantage was statistically significant in all subgroups except for patients with primary tumor less than 3 cm and for patients with less than 4 positive nodes. Estimated 2-year survival rates were 9,6% for FAC-BCG patients and 86% for control (p = .02). Treatment was well tolerated. Adjuvant FAC-BCG seems effective in prolonging disease-free interval and early survival in patients with stage II and III breast cancer. Its long term efficacy will require longer follow-ups.
在过去34个月里，对5-氟尿嘧啶、阿霉素、环磷酰胺和卡介苗（FAC-BCG）联合用药作为腋窝淋巴结阳性的II期和III期乳腺癌患者辅助治疗进行了评估。在接受FAC-BCG治疗的131例患者组中，术后2年无病生存率估计为91%，而151例历史对照患者组的估计无病生存率为69%（p<0.01）。除原发肿瘤小于3 cm的患者和阳性淋巴结少于4个的患者外，这一优势在所有亚组中均具有统计学意义。FAC-BCG组患者的2年估计生存率为96%，对照组为86%（p = 0.02）。治疗耐受性良好。辅助性FAC-BCG似乎能有效延长II期和III期乳腺癌患者的无病间期和早期生存率。其长期疗效需要更长时间的随访。
